Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLB1 | P16278 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 4/20 | 0.46 |
| ▸ | GUSB | P08236 | 2/20 | 0.44 |
| ▸ | EBP | Q15125 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | GBA2 | Q9HCG7 | 6/20 | 0.35 |
| ▸ | UGCG | Q16739 | 3/20 | 0.35 |
| ▸ | MGAM | O43451 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | SI | P14410 | 2/20 | 0.35 |
| ▸ | AGL | P35573 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13607403 | 0.93 | GUSB (0.52) | GLB1GBA1GUSBEBPSIGMAR1 | |
| SCHEMBL9974273 | 0.86 | — | — | |
| SCHEMBL12912029 | 0.84 | GNAI3 (0.42) | GLB1SIGMAR1 | |
| SCHEMBL14749186 | 0.84 | GNAI3 (0.42) | GLB1SIGMAR1 | |
| SCHEMBL14749169 | 0.84 | GNAI3 (0.42) | GLB1SIGMAR1 | |
| SCHEMBL12911893 | 0.81 | BCHE (0.45) | — | |
| SCHEMBL14968346 | 0.80 | GBA1 (0.38) | GLB1GBA1GUSBEBPSIGMAR1 | |
| SCHEMBL2248287 | 0.80 | KEAP1 (0.39) | GLB1SIGMAR1 | |
| SCHEMBL14968345 | 0.80 | EBP (0.34) | GLB1GUSBEBPSIGMAR1 | |
| SCHEMBL23386789 | 0.78 | CYP2D6 (0.39) | GLB1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759781-B2 | Substituted guanidine derivatives | UBE INDUSTRIES, LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | MUSK, FGFR1, PDGFRA | GLB1 4550/4885GBA1 2661/4885GUSB 4837/4885 |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | LTK, MUSK, FGFR1 | GLB1 3601/4885GBA1 2329/4885GUSB 4736/4885 |
| US-10759781-B2 | Substituted guanidine derivatives | GMPS, GUCY1A1, GUCY1A2 | GLB1 911/4885GBA1 107/4885GUSB 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.